Arcus Biosciences Inc. (NYSE:RCUS) has a beta value of 0.86 and has seen 1.16 million shares traded in the last trading session. The company, currently valued at $1.57B, closed the last trade at $22.02 per share which meant it gained $0.76 on the day or 3.57% during that session. The RCUS stock price is -80.52% off its 52-week high price of $39.75 and 23.98% above the 52-week low of $16.74. If we look at the company’s 10-day average daily trading volume, we find that it stood at 1.41 million shares traded. The 3-month trading volume is 1.22 million shares.
The consensus among analysts is that Arcus Biosciences Inc. (RCUS) is a Buy stock at the moment, with a recommendation rating of 1.80. 0 analysts rate the stock as a Sell, while 1 rate it as Overweight. 2 out of 13 have rated it as a Hold, with 10 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -$1.07.
Arcus Biosciences Inc. (NYSE:RCUS) trade information
Sporting 3.57% in the green in last session, the stock has traded in the green over the last five days, with the highest price hit on Monday, 01/23/23 when the RCUS stock price touched $22.02 or saw a rise of 0.77%. Year-to-date, Arcus Biosciences Inc. shares have moved 6.48%, while the 5-day performance has seen it change 8.05%. Over the past 30 days, the shares of Arcus Biosciences Inc. (NYSE:RCUS) have changed 6.95%. Short interest in the company has seen 7.33 million shares shorted with days to cover at 4.88.
Wall Street analysts have a consensus price target for the stock at $43.42, which means that the shares’ value could jump 49.29% from current levels. The projected low price target is $24.00 while the price target rests at a high of $70.00. In that case, then, we find that the current price level is -217.89% off the targeted high while a plunge would see the stock gain -8.99% from current levels.
Arcus Biosciences Inc. (RCUS) estimates and forecasts
Figures show that Arcus Biosciences Inc. shares have underperformed across the wider relevant industry. The company’s shares have lost -17.96% over the past 6 months, with this year growth rate of -640.85%, compared to 4.50% for the industry. Other than that, the company has, however, lowered its growth outlook for the 2023 fiscal year revenue. Growth estimates for the current quarter are -128.80% and -20.80% for the next quarter. Revenue growth from the last financial year stood is estimated to be -73.30%.
9 analysts offering their estimates for the company have set an average revenue estimate of $23.31 million for the current quarter. 6 have an estimated revenue figure of $22.5 million for the next quarter concluding in Mar 2023. Year-ago sales stood $354.5 million and $18 million respectively for this quarter and the next, and analysts expect sales will shrink by -93.40% for the current quarter and 25.00% for the next.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 29.60% over the past 5 years.
Arcus Biosciences Inc. is expected to release its next earnings report between February 21 and February 27 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Arcus Biosciences Inc. (NYSE:RCUS)’s Major holders
Insiders own 28.87% of the company shares, while shares held by institutions stand at 75.26% with a share float percentage of 105.81%. Investors are also buoyed by the number of investors in a company, with Arcus Biosciences Inc. having a total of 273 institutions that hold shares in the company. The top two institutional holders are Blackrock Inc. with over 8.93 million shares worth more than $196.6 million. As of Sep 29, 2022, Blackrock Inc. held 12.33% of shares outstanding.
The other major institutional holder is Vanguard Group, Inc. (The), with the holding of over 4.46 million shares as of Sep 29, 2022. The firm’s total holdings are worth over $98.15 million and represent 6.16% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are iShares Core S&P Smallcap ETF and Fidelity Select Portfolios – Biotechnology. As of Dec 30, 2022, the former fund manager holds about 5.35% shares in the company for having 3.88 million shares of worth $85.38 million while later fund manager owns 3.19 million shares of worth $70.32 million as of Nov 29, 2022, which makes it owner of about 4.41% of company’s outstanding stock.